As cancer cells overexpress the NK-1R, two different therapeutic strategies could be used not only against glioma but against any tumor type: pharmacological, using NK-1R antagonists [26, 47, 48, 61, 62], and/or genetic by applying the TAC1R siRNA method [3, 15]. This evidence concerns the gene TACR1 and glioma.